NEW YORK – MiR Scientific is preparing to launch a suite of non-invasive microRNA-based cancer tests that it hopes can improve prostate and bladder cancers diagnoses and help guide clinical decision-making through other stages of the prostate cancer care continuum.
In support of its prostate cancer testing suite in particular, the firm recently published a comprehensive validation study describing the development of the three assays and reporting their sensitivity and specificity in a case-control training and validation cohort of about 1,400 samples.